Available Technologies: Detecting and Treating Breast Cancer Resistance to EGFR Inhibitors

ABSTRACT:

Mina Bissell and colleagues at Berkeley Lab have developed therapeutic compositions and methods related to inhibition of FAM83A as well as methods of diagnosing cancer resistance to EGFR inhibitors.

For details, see the published PCT application for this technology, WO2010/12055, available at www.wipo.int.

FOR MORE INFORMATION:

http://newscenter.lbl.gov/news-releases/2012/09/11/fam83a-oncogene-discovered/

Lee, S., Meier, R., Furuta, S., Lenburg, M., Kenny, P., Xu, R., and Bissell, M. "FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice," Journal of Clinical Investigation (JCI), 2012, 122(9):3211–3220.

STATUS: Published PCT application WO2010/120554 available www.wipo.int. Available for licensing or collaborative research.

SEE THESE OTHER BERKELEY LAB TECHNOLOGIES IN THIS FIELD:

TACE Inhibition for Treating High Risk Cancers and Enhancing Current EGFR Therapies, IB-2188

REFERENCE NUMBER: IB-2578